GSK acquires Chimagen trispecific T-cell engager programme in deal worth up to $750m
GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.
The programme is designed to engage T cells against multiple myeloma through a trispecific antibody approach, adding another differentiated immuno-oncology asset to GSK's haematology pipeline.
Chimagen is eligible for upfront and milestone payments worth up to $750 million, while GSK will assume responsibility for further global development and commercialisation of the programme.
Field | Content |
Alert Type | Deal |
Companies | GSK; Chimagen Biosciences |
Deal Type | Global rights acquisition / licensing agreement |
Asset or Company | Trispecific T-cell engager programme |
Therapy Area(s) | Oncology; haematology; multiple myeloma |
Technology or Modality | Trispecific T-cell engager |
Deal Value | Up to US$750 million in upfront and milestone payments |
Geography | Global |
What Happened | GSK acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma. |
Why It Matters | The deal adds a potentially differentiated next-generation immunotherapy to GSK's multiple myeloma pipeline and strengthens its position in haematologic oncology. |
Supporting Context | The programme uses a trispecific antibody design intended to direct T cells against tumour targets associated with multiple myeloma. |
Strategic Rationale | GSK gains control of an innovative early-stage oncology programme while Chimagen receives near- and long-term economics tied to development and commercial success. |
Potential Impact | Successful development could provide a new treatment approach for patients with multiple myeloma and strengthen competition in the T-cell engager field. |
Key Takeaway | GSK is committing up to US$750 million for global rights to Chimagen's trispecific T-cell engager programme in multiple myeloma. |
What to Watch | Entry into clinical development, early safety and efficacy data and positioning against other T-cell engager and cell-therapy approaches in multiple myeloma. |
Primary Source | GSK |
Relevant Date | 15 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments